FDA DDMAC Personnel Changes
Ken Feather has returned to the Division of Drug Marketing, Advertising and Communications after a nine-month detail to the Center for Devices and Radiological Health. Feather will initially succeed Edward Zimney, MD, as chief of the marketing surveillance and enforcement branch that has purview over drugs approved by the Office of Drug Evaluation II. Zimney joined Immunex on March 7 as head of the Seattle company's Drug Safety department. Feather will eventually move into an advisory position with division-wide responsibilities, such as internal consistency in monitoring and surveillance, quality assurance issues, policy making and training
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth